PI3K Pathway Inhibitors: Better Not Left Alone (original) (raw)

Challenges in the clinical development of PI3K inhibitors

Cristian Massacesi

Annals of the New York Academy of Sciences, 2013

View PDFchevron_right

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Anindita Chakrabarty

Oncotarget, 2011

View PDFchevron_right

Targeting PI3K in Cancer: Any Good News?

Miriam Martini

Frontiers in Oncology, 2013

View PDFchevron_right

First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer

Jorge Gallo, Lixin Han

View PDFchevron_right

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway

Pascal Furet

Future Medicinal Chemistry, 2009

View PDFchevron_right

Status of PI3K inhibition and biomarker development in cancer therapeutics

Josep Tabernero

Annals of …, 2010

View PDFchevron_right

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

carlos rubio arteaga

Cancer Discovery, 2019

View PDFchevron_right

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Samar Alanazi

International Journal of Molecular Sciences

View PDFchevron_right

PI3 kinase inhibitors in the clinic: an update

jean emmanuel kurtz

Anticancer research, 2012

View PDFchevron_right

Targeting PI3K/mTOR signaling in cancer

Alexandre Arcaro

Frontiers Research Topics, 2014

View PDFchevron_right

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

Phillip Dennis

Drug Resistance Updates, 2008

View PDFchevron_right

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Kyle Edgar, John Lesnick

Molecular Cancer Therapeutics, 2011

View PDFchevron_right

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

Charles Sawyers

Cancer Cell, 2015

View PDFchevron_right

Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

Asif Khurshid Qazi

Anti-Cancer Agents in Medicinal Chemistry, 2013

View PDFchevron_right

Targeting PI3K/Akt/mTOR Signaling in Cancer

Alessandra Mosca

Frontiers in oncology, 2014

View PDFchevron_right

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

Stacy Moulder, Razelle Kurzrock

Cell reports, 2014

View PDFchevron_right

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment

Ana Bosch

Molecular & Cellular Oncology, 2014

View PDFchevron_right

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Bharani Bharani-Dharan

OncoTargets and Therapy, 2016

View PDFchevron_right

Inhibiting PI3K as a therapeutic strategy against cancer

Luis Paz-ares, Amancio Carnero

Clinical and Translational Oncology, 2009

View PDFchevron_right

DEVELOPMENT OF DRUGS TARGETING THE PI3K SIGNALLING PATHWAY IN LEUKAEMIAS AND LYMPHOMAS

Alexandre Arcaro

View PDFchevron_right

PI3K/Akt signalling pathway and cancer

JAVIER CASTRO

Cancer Treatment Reviews, 2004

View PDFchevron_right

The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells

Mohamed Badr

Journal of Cancer and Biomedical Research, 2019

View PDFchevron_right

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

Xiangnan Du

Molecular Cancer Therapeutics, 2014

View PDFchevron_right

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

xiaobei zhang

Current Cancer Drug Targets, 2013

View PDFchevron_right

Inhibiting the RAS-PI3K pathway in cancer therapy

Julian Downward

The Enzymes, 2013

View PDFchevron_right

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

Julian Downward

2012

View PDFchevron_right

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy

Mike-Andrew Westhoff

Molecular and Cellular Therapies, 2014

View PDFchevron_right

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges

Keerti Jain

Drug Discovery Today, 2019

View PDFchevron_right

The selective PI3K inhibitor XL147 (SAR245408) inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

Wendy Abulafia, Paul Keast, Sanh Lam, Charles Marlowe

Molecular cancer therapeutics, 2015

View PDFchevron_right

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

Jinjiang Zhu

Clinical Cancer Research, 2014

View PDFchevron_right

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Minghao sun

Molecular Cancer Therapeutics, 2011

View PDFchevron_right